Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome

• DOI: 10.1016/j.jdcr.2022.02.022
• Publication Date: 2022-03-02T17:13:42Z
• Authors: Amrita Goyal; Damodaran Narayanan; Waihay Wong; Alvaro C. Laga; Nathan T. Connell; Susan Y. Ritter; Gabriela Cobos
• Keywords: tocilizumab; 03 medical and health sciences; 0302 clinical medicine; RL1-803; relapsing polychondritis; autoinflammatory; Case Report; Dermatology; myelodysplasia; ubiquitination; UB1A